Nasus Pharma is trading 6.1% down at $2.75 in pre-market, extending last week’s volatility after speculative gains and a subsequent pullback.
- The move appears to be a continuation of recent trading momentum rather than a reaction to fresh company-specific news.
- There are currently no new SEC filings, press releases, or major analyst calls regarding the company this morning.